Percutaneous coronary intervention before noncardiac surgery: more threat than benefit?  by Mendoza, Cesar E et al.
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pisk of Noncardiac Surgery in
he Months Following Placement
f a Drug-Eluting Coronary Stent
e read with great interest the retrospective study by Wilson et al.
1) in a recent issue of the Journal. The study provides data
uggesting that, whenever possible, noncardiac surgery should be
elayed six weeks after placement of a coronary stent. By that time
course of antiplatelet therapy to prevent stent thrombosis has
sually been completed, and bare metal stents are generally
ndothelialized.
Today, drug-eluting stents are increasingly utilized to reduce
he risk of restenosis. Elution of antiproliferative agents delays
ndothelialization (2,3), which, consequently, may increase the risk
f subacute and late stent thrombosis. Therefore, a prolonged
ourse of antiplatelet therapy has been recommended with the use
f drug-eluting stents (4). Thus, the conclusion drawn from the
tudy by Wilson et al. (1) is strictly confined to bare metal stents
nd is not applicable for drug-eluting stents.
We recently observed a patient who simultaneously received a
are metal stent (3.5  13 mm at right coronary artery [RCA])
nd two paclitaxel-eluting stents (both 2.5  16 mm at the left
ircumflex coronary artery [LCX]) for stable angina and double-
essel coronary artery disease. A six-month course of combined
ntiplatelet therapy (clopidogrel 75 mg daily and aspirin 100 mg
aily) to prevent stent thrombosis was prescribed. At 12 weeks
ollowing stent placement, surgery for meniscopathy at the left
nee was performed after cessation of both antiplatelet agents.
wo hours following surgery, the patient developed chest pain.
ubsequently, myocardial infarction (MI) was confirmed by elec-
rocardiography and by biochemical markers. The patient was
ransferred to our institution one day after surgery for cardiac
atheterization. Coronary angiography revealed total occlusion of
oth paclitaxel-eluting stents at the LCX. The bare stent at the
CA was unremarkable. Recanalization of the occluded stents was
erformed successfully.
Stent thrombosis is a highly morbid complication of coronary
tenting (5,6). With the use of combined antiplatelet therapy, the
requency of stent thrombosis has been reduced dramatically (7).
owever, noncardiac surgery soon after coronary stenting is
ssociated with a high rate of MI and death (8). The present data
1) nicely demonstrate that delaying noncardiac surgery for up to
ix weeks after stent placement and completing a course of
ntiplatelet therapy with a thienopyridine is associated with a low
requency of stent thrombosis and other adverse events. However,
his recommendation has to be strictly confined to bare metal
tents. Following drug-eluting stent placement, elective noncardiac
urgery should be delayed for several months, by which time those
tents are generally endothelialized, and a course of prolonged
ombined antiplatelet therapy to prevent stent thrombosis has been
ompleted.
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ercutaneous Coronary
ntervention Before Noncardiac
urgery: More Threat Than Benefit?
e read with great interest the report by Wilson et al. (1) entitled
Clinical Outcome of Patients Undergoing Non-Cardiac Surgery
n the Two Months Following Coronary Stenting.” This very
nteresting study supports previous evidence that both percutane-
us transluminal coronary angioplasty (PTCA) and coronary
tenting increase adverse perioperative cardiac events (2–4).
In their study, the investigators reported that 8 (4%) of 207
atients undergoing noncardiac surgery (NCS) in the two months
ollowing successful coronary stenting had major adverse cardiac
vents. All 8 patients were among the 168 patients who underwent
urgery within six weeks after coronary stent placement. No major
vents were observed in the remaining 39 patients undergoing
urgery 6 weeks after stent placement. These data indicate that
he risk of stent thrombosis is increased when surgery is carried out
n the six weeks following the coronary intervention. In contrast to
rior reports (3,4), Wilson et al. (1) did not identify an increased
ncidence of major hemorrhagic complications in the study popu-
ation. As the researchers wisely stated in their study, the inability
o determine a relationship among antiplatelet therapy, time to
urgery, and bleeding should be interpreted with great caution.
arge prospective studies will be necessary to clarify the results
rovided by the available small retrospective studies.
We recently performed a systematic review of the available
iterature in this regard (C. E. Mendoza et al., unpublished data,
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714 Letters to the Editor JACC Vol. 43, No. 4, 2004
February 18, 2004:713–5003). The main findings were: 1) the evidence supporting the use of
TCA prior to NCS as a strategy to lower the rate of perioperative
dverse cardiac outcomes is limited and inconclusive; moreover, the
argest reported study (2) showed serious adverse outcomes in patients
ubjected to NCS within 90 days of PTCA; and 2) coronary stenting
erformed shortly before NCS (especially during first two weeks) is
ssociated with increased perioperative morbidity and mortality rates.
Antithrombotic therapy following percutaneous coronary inter-
ention (PCI) in patients requiring NCS has to balance the risk of
tent thrombosis against the risk of surgical bleeding. Systemic
nflammatory and procoagulatory responses occur after PCI (5,6);
hese may be amplified by major NCS (7), thus increasing the risk of
erioperative coronary thrombotic complications. Therefore, an anti-
hrombotic regimen effective in the nonsurgical setting may not be
ffective to prevent stent thrombosis, but it may be sufficient to cause
ajor surgical bleeding. Until further data are available, NCS follow-
ng PCI should be deferred whenever possible for at least four weeks,
llowing the completion of currently recommended antiplatelet ther-
py to prevent the thrombotic complications associated with PCI.
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EPLY
e thank Dr. Auer and colleagues for raising an important issue.
ll patients in our study were enrolled between 1990 and 2000,
efore drug-eluting stents (DESs) were available. Therefore, the
esults of our study and any conclusions they permit should only be
pplied to bare stents, and we explicitly stated that they should not
e applied to situations in which re-endothelialization is delayed,
uch as brachytherapy. bLittle is known about how patients ought to be managed prior
o noncardiac surgery in the DES era, an issue that has already
risen many times at the Mayo Clinic. The answer may differ
epending on which DES is being considered (1). The two studies
ited, revealing that use of DESs delays endothelialization, were
oth of paclitaxel-eluting stents, but the polymer, release mecha-
isms, stent design, and, in the Farb study, the animal model
rabbits) were too different to extrapolate to the TAXUS program.
ith the slow-release formulation on the paclitaxel stent being
ommercialized, approximately 10% of the paclitaxel is released by
0 days, whereas the remaining 90% remains in the polymer
ndefinitely. The clinical significance of this is unclear. In contrast,
irolimus has nearly entirely eluted from a Cypher stent within 30
o 45 days, essentially leaving a polymer-coated bare metal stent.
nimal models suggest that the sirolimus stent may not delay
e-endothelialization (2,3) but that the paclitaxel stent does (Dr.
. S. Schwartz, personal communication, January 12, 2004).
However, based on the design of the pivotal clinical trials
eading to approval of these stents (and not on what is known
bout the rate of re-endothelialization in humans), clopidogrel is
ecommended for two to three months following placement of a
irolimus-eluting stent and for six months following placement of
paclitaxel-eluting stent. Accordingly, until the clinical outcomes
f large numbers of patients who received a DES and who did not
omplete their assigned course of clopidogrel are analyzed, we
ecommend the following. If a patient requires noncardiac surgery
ithin two months of percutaneous coronary intervention (PCI),
nd the type of surgery (or surgeon) will not permit continuing
spirin and clopidogrel throughout the perioperative period, we
uggest a DES not be used (although it is possible that a
irolimus-eluting stent might be safe in this setting); we recom-
end a non-DES stent, perhaps one that might possibly reduce
hrombosis without clopidogrel on-board during the pro-
hrombotic state of surgery, such as a heparin-coated or
hosphorylcholine-coated stent (though it must be emphasized
hat it is entirely unproven that such stents do indeed reduce stent
hrombosis in humans, let alone following noncardiac surgery). It
s also possible that balloon angioplasty alone is a reasonable option
or certain lesion types and clinical situations prior to noncardiac
urgery if a satisfactory result can be achieved.
We also thank Dr. Mendoza and colleagues for their interest in
ur study. We agree that our investigation was severely limited in
ts ability to detect the relationship between the concomitant
ntiplatelet therapy administered following preoperative PCI, time
o surgery, and perioperative bleeding; undoubtedly such a rela-
ionship exists. Our study does not, however, demonstrate, or even
ddress, whether preoperative PCI increases adverse perioperative
ardiac events. Preoperative PCI was performed in most patients
ncluded in our study in an attempt to reduce such events, although
e agree that data are lacking whether it actually does so. We
upport the call by Mendoza and colleagues for large prospective
tudies of this issue; fortunately, several are underway. In the
eantime, the choice of either stent (bare metal vs. drug eluting)
r reliance on balloon angioplasty without stent placement is an
mportant consideration for the interventionalist performing revas-
ularization on high-risk patients who might possibly benefit from
evascularization before undergoing high-risk surgery. We are of
he opinion, however, that most patients with coronary disease in
hom noncardiac surgery is planned do not require preoperative
evascularization. In general, the indications for revascularization
efore noncardiac surgery are the same as in patients in whom
